Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
LETTER TO THE EDITOR
Comment on: Eosinophilic granulomatosis with polyangiitis across the eosinophilic spectrum: from molecular mechanisms to practical differential diagnosis and targeted therapy
1
Department of Rheumatology and Immunology, Jagiellonian University Medical College, Krakow, Poland
Submission date: 2026-01-15
Final revision date: 2026-02-05
Acceptance date: 2026-02-23
Publication date: 2026-02-27
Corresponding author
Joanna Kosałka-Węgiel
Department of Rheumatology and Immunology, Jagiellonian University Medical College, Krakow, Poland
Department of Rheumatology and Immunology, Jagiellonian University Medical College, Krakow, Poland
Reumatologia 2026;64(1):72-73
TOPICS
REFERENCES (14)
1.
Hus A, Wisłowska M. Eosinophilic granulomatosis with polyangiitis across the eosinophilic spectrum: from molecular mechanisms to practical differential diagnosis and targeted therapy. Rheumatology 2026; 64: 46–51, DOI: 10.5114/reum/214426.
2.
Mattioli I, Urban ML, Padoan R, et al. Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): a European real-life retrospective comparative study. J Autoimmun 2025; 153: 103398. DOI: 10.1016/j.jaut.2025.103398.
3.
Sebastian A, Kosałka-Węgiel J. A variety of clinical presentations of eosinophilic granulomatosis with polyangiitis: a comprehensive review. Rheumatology 2024; 62: 456–465, DOI: 10.5114/reum/196141.
4.
Kosałka-Węgiel J, Sebastian A. Dual pathogenesis and treatment approaches for eosinophilic granulomatosis with polyangiitis:a comprehensive review. Rheumatology 2025; 63: 331–336, DOI: 10.5114/reum/211785.
5.
Shiomi M, Watanabe R, Ishihara R, et al. Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies. Biomolecules 2025; 15: 544, DOI: 10.3390/biom15040544.
6.
Nair PK, Hellmich B, Bourdin A, et al. The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis. Arthritis Rheumatol 2025, DOI: 10.1002/art.43398.
7.
Koga Y, Aoki-Saito H, Kamide Y, et al. Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis. Front Pharmacol 2022; 13: 865318, DOI: 10.3389/fphar.2022.865318.
8.
Mümmler C, Mertsch P, Barnikel M, et al. Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis. J Asthma Allergy 2024; 17: 557–572, DOI: 10.2147/JAA.S461800.
9.
Spataro F, Solimando AG, Di Girolamo A, et al. Efficacy and safety of benralizumab in eosinophilic granulomatosis with polyangiitis: A meta-analysis of eight studies. Eur J Clin Invest 2025; 55: e14333, DOI: 10.1111/eci.14333.
10.
Merkel PA, Nair PK, Khalidi N, et al. Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis 2025; 84: 1888–1899, DOI: 10.1016/j.ard.2025.06.2131.
11.
Menzella F, Galeone C, Ghidoni G, et al. Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab. Multidiscip Respir Med 2021; 16: 779, DOI: 10.4081/mrm.2021.779.
12.
Kosałka-Węgiel J, Milewski M, Siwiec A, et al. Severe hypereosinophilic syndrome successfully treated with a monoclonal antibody against interleukin 5 receptor a – benralizumab. Cent Eur J Immunol 2021; 46: 395–397, DOI: 10.5114/ceji.2021.108259.
13.
Wechsler ME, Nair P, Terrier B, et al. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med 2024; 390: 911–921, DOI: 10.1056/NEJMoa2311155.
14.
Jackson DJ, Shavit A, Ding N, et al. Systematic Literature Review of Real-World Outcomes of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis. J Allergy Clin Immunol Pract 2025; 13: 3054–3065.e4, DOI: 10.1016/j.jaip.2025.08.028.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
